Published in Cancer Weekly, June 18th, 2002
Clinical investigators also reported that Panzem, taken orally as a capsule, was safe and well tolerated and demonstrated signs of inhibiting blood vessel growth associated with the disease. The data were presented at the American Society of Clinical Oncology Annual Meeting in Orlando, Florida.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.